Research Impact

h-index

N/A

Research impact score

Publications

Total publications

Trial Results

Published trial results

Citations

Total citations

Drug Portfolio

DRUG(9)

BIOLOGICAL(8)

MIXED(6)

DEVICE(1)

ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab

2 trials

phase_2

second-affiliated-hospital-of-guangzhou-medical-university

ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab

2 trials

phase_2

second-affiliated-hospital-of-guangzhou-medical-university

Neoantigen mRNA Vaccine

1 trial

phase_1

second-affiliated-hospital-of-guangzhou-medical-university

DC cell Vaccine

1 trial

phase_1

second-affiliated-hospital-of-guangzhou-medical-university

CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells

1 trial

early_phase_1

second-affiliated-hospital-of-guangzhou-medical-university

IRSW-MIM

1 trial

phase_2_3

second-affiliated-hospital-of-guangzhou-medical-university

PD1/PDL1/CTLA4 inhibitors

1 trial

phase_2_3

second-affiliated-hospital-of-guangzhou-medical-university

Cell therapy for solid tumors

1 trial

phase_1

second-affiliated-hospital-of-guangzhou-medical-university

+14 more interventions

22 unique interventions4 categories

Analytics

Trial Phases

Phase 111

Phase 211

Phase 33

Trial Status

Recruiting20

Other1

Role Distribution

Principal Investigator21

PI Rate100%

Activity Timeline

Clinical Trials (20)

NCT06492408Phase 2Recruiting

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Hepatic CancerSurgery

PrincipalinvestigatorStart date: 2024-07-01

NCT06492421Phase 2Recruiting

Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.

Lung CancerNon-small Cell Lung CancerSurgery

PrincipalinvestigatorStart date: 2024-07-01

NCT06482801Phase 2Recruiting

Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

AntibodyLiver Cancer

PrincipalinvestigatorStart date: 2024-06-10

NCT06477614Phase 1Recruiting

Anti-cancer DC Cell Vaccination to Treat Solid Tumors

DCSolid Tumor, Adult

PrincipalinvestigatorStart date: 2024-06-05

NCT06195293Phase 1Recruiting

Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors

Solid Tumor, Adult

PrincipalinvestigatorStart date: 2024-06-04

NCT06196294Phase 1Recruiting

GPC3/Mesothelin-CAR-γδT Cells Against Cancers

CAR-T Cell TherapyLiver CancerLung Cancer+3 more

PrincipalinvestigatorStart date: 2024-05-10

NCT06195384Phase 1Recruiting

Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors

Solid Tumor, Adult

PrincipalinvestigatorStart date: 2024-05-08

NCT06483347Phase 2Recruiting

Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT

Inoperable DiseaseLung Cancer

PrincipalinvestigatorStart date: 2024-04-04

NCT06478108Phase 2/3Recruiting

Interventional Software for Multi-immunotherapy of Solid Tumors

Liver CancerLung CancerSolid Tumor, Adult

PrincipalinvestigatorStart date: 2024-04-01

NCT05779917Phase 1Recruiting

Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers

CAR-T Cell TherapyMesothelinPancreas Cancer+1 more

PrincipalinvestigatorStart date: 2023-03-10

Showing 10 of 20 trials

Research Network

Collaboration Network

2 collaborators·1 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Solid Tumor, Adult9 Cancer of Liver7 Lung Cancer7 Carcinoma, Hepatocellular3 Cancer of Pancreas3 Breast Cancer2 Chimeric Antigen Receptor Therapy2 Colorectal Cancer2

Affiliations

Second Affiliated Hospital of Guangzhou Medical University

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Hui Lian, MD

Second Affiliated Hospital of Guangzhou Medical University

2 trials

Shared therapeutic areas:

Head/Neck NeoplasmCancer of Liver

Worked with same sponsors:

Second Affiliated Hospital of Guangzhou Medical University

Collaborated on 2 trials

Similarity Score28%

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

32 trials

Shared therapeutic areas:

Breast CancerCarcinoma, Non-Small-Cell LungOvary Cancer+6 more

Similarity Score8%

Dong-Xin Wang, MD, PhD

Peking University First Hospital

74 trials

Shared therapeutic areas:

General SurgeryLung CancerBrain Neoplasms+4 more

Similarity Score6%

Lin Shen, MD

Peking University Cancer Hospital & Institute

20 trials

Shared therapeutic areas:

Cancer of StomachCancer of PancreasColorectal Cancer+4 more

Similarity Score6%

Mark Levine, MD

Ontario Clinical Oncology Group (OCOG)

13 trials

Shared therapeutic areas:

Breast CancerBrain NeoplasmsColorectal Cancer+4 more

Similarity Score6%

Aminah Jatoi, MD

Mayo Clinic

29 trials

Shared therapeutic areas:

Cancer of EsophagusLung CancerCancer of Stomach+2 more

Similarity Score4%

Lizhi Niu, PhD

Fuda Cancer Hospital

31 trials

Shared therapeutic areas:

Cancer of LiverCancer of PancreasBreast Cancer+1 more

Similarity Score4%

Jeong Min Lee, MD

Seoul National University Hospital

34 trials

Shared therapeutic areas:

Carcinoma, HepatocellularColorectal CancerCancer of Liver+1 more

Similarity Score4%

You Lu, MD

West China Hospital

18 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell LungLung CancerCancer of the Uterine Cervix+1 more

Similarity Score4%

Francesco Perrone, M.D., Ph.D.

National Cancer Institute, Naples

13 trials

Shared therapeutic areas:

Ovary CancerCancer of the Uterine CervixCarcinoma, Non-Small-Cell Lung+1 more

Similarity Score4%

Publications (0)

No publications found for this investigator.

Clinical Trials (21)

Showing 20 of 21 trials

NCT06492408Phase 2PrincipalInvestigator

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Hepatic CancerSurgery

Recruiting

NCT06492421Phase 2PrincipalInvestigator

Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.

Lung CancerNon-small Cell Lung CancerSurgery

Recruiting

NCT06482801Phase 2PrincipalInvestigator

Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

AntibodyLiver Cancer

Recruiting

NCT06477614Phase 1PrincipalInvestigator

Anti-cancer DC Cell Vaccination to Treat Solid Tumors

DCSolid Tumor, Adult

Recruiting

NCT06195293Phase 1PrincipalInvestigator

Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors

Solid Tumor, Adult

Recruiting

NCT06196294Phase 1PrincipalInvestigator

GPC3/Mesothelin-CAR-γδT Cells Against Cancers

CAR-T Cell TherapyLiver CancerLung Cancer+3 more

Recruiting

NCT06195384Phase 1PrincipalInvestigator

Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors

Solid Tumor, Adult

Recruiting

NCT06483347Phase 2PrincipalInvestigator

Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT

Inoperable DiseaseLung Cancer

Recruiting

NCT06478108Phase 2/3PrincipalInvestigator

Interventional Software for Multi-immunotherapy of Solid Tumors

Liver CancerLung CancerSolid Tumor, Adult

Recruiting

NCT05779917Phase 1PrincipalInvestigator

Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers

CAR-T Cell TherapyMesothelinPancreas Cancer+1 more

Recruiting

NCT05410717Phase 1PrincipalInvestigator

CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors

CAR NKEndometrial Cancer RecurrentStage IV Ovarian Cancer+1 more

Recruiting

NCT05187338Phase 1/2PrincipalInvestigator

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

Breast CancerCervical CancerColorectal Cancer+8 more

Recruiting

NCT04952272Phase 1PrincipalInvestigator

Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors

Hepatocellular CarcinomaLung CancerSolid Tumor

Recruiting

NCT04803318Phase 2PrincipalInvestigator

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Hepatocellular CarcinomaSolid Tumor, Adult

Recruiting

NCT04842812Phase 1PrincipalInvestigator

Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

Brain TumorBreast CancerColo-rectal Cancer+5 more

Recruiting

NCT04770207Phase 2PrincipalInvestigator

Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs

Hepatocellular CarcinomaSolid Tumor, Adult

Recruiting

NCT05060796Early Phase 1PrincipalInvestigator

Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC

Non Small Cell Lung Cancer

Recruiting

NCT03882840Phase 1/2PrincipalInvestigator

Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I

Anti-cancer Cell ImmunotherapyT Cell and NK Cell

Recruiting

NCT03949231Phase 3PrincipalInvestigator

Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma

Liver Cancer

Recruiting

NCT03952065Phase 2/3PrincipalInvestigator

IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC)

Head/Neck Neoplasm

Recruiting